GENMAB A/S (GE9.DE) Stock Price & Overview
FRA:GE9 • DK0010272202
The current stock price of GE9.DE is 231.9 EUR. Today GE9.DE is down by -1.9%. In the past month the price decreased by -13.11%.
GE9.DE Key Statistics
- Market Cap
- 142.849B
- P/E
- 15.71
- Fwd P/E
- 18.50
- EPS (TTM)
- 14.76
- Dividend Yield
- N/A
GE9.DE Stock Performance
GE9.DE Stock Chart
GE9.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GE9.DE.
GE9.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GE9.DE. Both the health and profitability get an excellent rating, making GE9.DE a very profitable company, without any liquidiy or solvency issues.
GE9.DE Earnings
On February 18, 2026 GE9.DE reported an EPS of 2.13 and a revenue of 1.06B. The company missed EPS expectations (-39.11% surprise) and beat revenue expectations (0.19% surprise).
GE9.DE Forecast & Estimates
26 analysts have analysed GE9.DE and the average price target is 307.95 EUR. This implies a price increase of 32.8% is expected in the next year compared to the current price of 231.9.
For the next year, analysts expect an EPS growth of -15.07% and a revenue growth 18.34% for GE9.DE
GE9.DE Groups
Sector & Classification
GE9.DE Financial Highlights
Over the last trailing twelve months GE9.DE reported a non-GAAP Earnings per Share(EPS) of 14.76. The EPS decreased by -2.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.89% | ||
| ROA | 7.48% | ||
| ROE | 16.47% | ||
| Debt/Equity | 0.88 |
GE9.DE Ownership
GE9.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 26.13 | 38.504B | ||
| 1AE | ARGENX SE | 25.73 | 38.43B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.836B | ||
| 2X1 | ABIVAX SA | N/A | 7.449B | ||
| ABVX | ABIVAX SA | N/A | 7.433B | ||
| GXE | GALAPAGOS NV | N/A | 1.86B | ||
| GLPG | GALAPAGOS NV | N/A | 1.856B | ||
| NANO | NANOBIOTIX | N/A | 1.386B | ||
| 6IV | INVENTIVA SA | N/A | 1.094B | ||
| IVA | INVENTIVA SA | N/A | 1.071B | ||
| PHIL | PHILOGEN SPA | 17.61 | 628.66M | ||
| GNFT | GENFIT | 872.06 | 426.025M | ||
| XUP | GENFIT | N/A | 425.025M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About GE9.DE
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
GENMAB A/S
Carl Jacobsens Vej 30
Valby DK
Employees: 2682
Phone: 4570202728
GENMAB A/S / GE9.DE FAQ
Can you describe the business of GENMAB A/S?
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Can you provide the latest stock price for GENMAB A/S?
The current stock price of GE9.DE is 231.9 EUR. The price decreased by -1.9% in the last trading session.
Does GENMAB A/S pay dividends?
GE9.DE does not pay a dividend.
What is the ChartMill rating of GENMAB A/S stock?
GE9.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the analyst forecast for GE9.DE stock?
26 analysts have analysed GE9.DE and the average price target is 307.95 EUR. This implies a price increase of 32.8% is expected in the next year compared to the current price of 231.9.
What sector and industry does GENMAB A/S belong to?
GENMAB A/S (GE9.DE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for GE9 stock?
The PE ratio for GENMAB A/S (GE9.DE) is 15.71. This is based on the reported non-GAAP earnings per share of 14.76 and the current share price of 231.9 EUR.